#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Liver transplantation – changes in indications over last decade


Authors: Pavel Trunečka
Authors‘ workplace: Klinika hepatogastroenterologie IKEM, Praha
Published in: Vnitř Lék 2019; 65(9): 588-594
Category:

Overview

To achieve satisfactory results of liver transplantation, proper selection of transplant candidates is essential. Moreover, indication process is crucial regulator to solve disparity between need for transplantation and capacity of transplant services. Any patient entering the transplant waiting list must have a chance to achieve at least average transplant benefit, currently described as 50% chance to survive 5 years after liver replacement. Until now, liver transplantation is procedure designed to treat life threatening liver disorders with aim to offer long-term survival. Nevertheless, an increase in incidence of hepatocellular carcinoma, and nonalcoholic fatty liver disease caused changes in indication spectrum. Improvement in intensive care turned interest to patients with acute-on-chronic liver failure even caused by acute alcoholic hepatitis. Advances in surgery and oncology broadened indications of patients with hepatocellular carcinoma behind standard criteria, and reopened interest in field of cholangiocellular cancer and even liver metastases of colorectal cancer. These criteria are still under development, and full of controversies and broad local variation in clinical practice is present. Entity of futile transplantation is discussed recently with aim to define generally acceptable criteria to deny transplant treatment in too risky patients.

Keywords:

cholangiocellular carcinoma – non-alcoholic fatty liver disease – futile transplantation – hepatocellular carcinoma – liver transplantation


Sources
  1. Newsletter transplant 2018 Council of Europe. Dostupné z WWW: <http://www.transplant-observatory.org/download/6732/
  2. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10(11): 686–690. Dostupné z DOI: <http://dx.doi.or/10.1038/nrgastro.2013.171>.
  3. Charlton MR, Burns JM, Pedersen RA et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141(4): 1249–1253. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2011.06.061>.
  4. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35(1): 105–109. Dostupné z DOI: <http://dx.doi.org/10.1053/jhep.2002.30318>.
  5. Spengler EK, O‘Leary JG, Te HS et al. Liver Transplantation in the Obese Cirrhotic Patient. Transplantation 2017; 101(10): 2288–2296. Dostupné z DOI: <http://dx.doi.org/10.1097/TP.0000000000001794>.
  6. Hejlova I, Honsova E, Sticova E et al. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl 2016; 22(5): 644–655. Dostupné z DOI: <http://dx.doi.org/10.1002/lt.24393>.
  7. Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44(4): 865–873. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.21327>,
  8. Pais R, Barritt AS, Calmus Y et al. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol 2016; 65(6): 1245–1257. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2016.07.033>.
  9. Putignano A, Gustot T. New concepts in acute-on-chronic liver failure: implications for liver transplantation. Liver transplantation 2017; 23(2): 234–243. Dostupné z DOI: <http://dx.doi.org/10.1002/lt.24654>.
  10. Thuluvath PJ, Thuluvath AJ, Hanish S et al. Liver transplantation in patients with multiple organ failures: Feasibility and outcomes. J Hepatol 2018; 69(5): 1047–1056. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2018.07.007>.
  11. Gustot T, Agarwal B. Selected patients with acute-on-chronic liver failure grade 3 are not too sick to be considered for liver transplantation. J Hepatol 2017; 67(4): 667–668. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2017.07.017>.
  12. Dutkowski, Oberkofler CE, Slankamenac K et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg 2011; 254(5): 745–753; discussion 753. Dostupné z DOI: <http://dx.doi.org/10.1097/SLA.0b013e3182365081>.
  13. Schrem H, Focken M, Gunson B et al. The new liver allocation score for transplantation is validated and improved transplant survival benefit in Germany but not in the United Kingdom. Liver Transpl 2016; 22(6): 743–756. Dostupné z DOI: <http://dx.doi.org/10.1002/lt.24421.
  14. Mathurin P, Moreno C, Samuel D et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1790–1800. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1105703>.
  15. Lee BP, Vittinghoff E, Hsu C et al. Predicting Low-Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The SALT Score. Hepatology 2018; <http://dx.doi.org/10.1002/hep.30478>.
  16. Gelu-Simeon M, Mathurin P. Liver Transplantation for Severe Alcoholic Hepatitis: Where Are We Now? Liver Transpl 2018; 24(10): 1327–1328. Dostupné z DOI: <http://dx.doi.org/10.1002/lt.25337>.
  17. Kulik L, Heimbach JK, Zaiem F et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67(1): 381–400. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.29485>.
  18. Yao FY, Mehta N, Flemming J et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61(6): 1968–1977. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.27752>.
  19. Cillo U, Vitale A, Polacco M et al. Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit. Hepatology 2017; 65(5): 1741–1748. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.28998>.
  20. Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10(3): 186–189. Dostupné z DOI: <http://dx.doi.org/10.1080/13651820801992542>.
  21. Darwish Murad S, Kim WR, Harnois DM et al. Efficacy of neoadjuvant chemoradiation, followed by live transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143(1): 88–98.e3; quiz e14. Dostupné z DOI: <http://dx,doi.org/10.1053/j.gastro.2012.04.008>.
  22. Mantel HT, Westerkamp AC, Adam R et al. Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. PLoS One 2016; 11(6): e0156127. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0156127>.
  23. Vilchez V, Shah MB, Daily MF et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) 2016; 18(1): 29–34. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hpb.2015.10.001>.
  24. Sapisochin G, Rodríguez de Lope C, Gastaca M et al. “Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant 2014; 14(3): 660–667. Dostupné z DOI: <http://dx.doi.org/10.1111/ajt.12591>.
  25. Sapisochin G, Facciuto M, Rubbia-Brandt L et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016; 64(4): 1178–1188. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.28744>.
  26. Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 2018; 24(2): 294–303. Dostupné z DOI: <http://dx.doi.org/10.1002/lt.24955>.
  27. Gorgen A, Muaddi H, Zhang W et al. The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. Can J Gastroenterol Hepatol 2018; 2018: 9531925. Dostupné z DOI: <http://dx.doi.org/10.1155/2018/9531925>.
  28. Hagness M, Foss A, Line PD et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013; 257(5): 800–806. Dostupné z DOI: <http://dx.doi.org/10.1097/SLA.0b013e3182823957>.
  29. Toso C, Pinto Marques H, Andres A et al. Liver transplantation for colorectal liver metastasis: Survival without recurrence can be achieved. Liver Transpl 2017; 23(8): 1073–1076. Dostupné z DOI: <http://dx.doi.org/10.1002/lt.24791>.
  30. Andres A, Oldani G, Berney T et al. Transplantation for colorectal metastases: on the edge of a revolution. Transl Gastroenterol Hepatol 2018; 3: 74. Dostupné z DOI: <http://dx.doi.org/10.21037/tgh.2018.08.04>.
  31. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693–699. Dostupné z DOI: <http://doi: 10.1056/NEJM199603143341104>.
  32. 32.Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33}6]: 1394–1403. Dostupné z DOI: <http://doi: 10.1053/jhep.2001.24563>.
Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#